But there is more to be done.
‘But there is more to be done, both for AYA care also to support survivorship programs that monitor patients following treatment for childhood malignancy.’ ‘Pediatric hematology/oncology nurses have long recognized the necessity to address the complicated problems of adolescents and young adults with malignancy who reside in the fringes between pediatric and adult oncology treatment settings uk online pharmacy . Studies also show that survival rates are compromised without the comprehensive services needed to face the challenges that lie before them,’ Echtenkamp stated.
APPRAISE-2 Study with Investigational Compound Apixaban Discontinued Bristol-Myers Squibb Firm and Pfizer reported that the firms have discontinued the Stage 3 APPRAISE-2 clinical trial in patients with recent Acute Coronary Syndrome treated with apixaban or placebo in addition to mono or dual antiplatelet therapy. The study was stopped early predicated on the recommendation of an independent Data Monitoring Committee . There is clear proof a clinically important increase in bleeding among patients randomized to apixaban. This increase in bleeding had not been offset by clinically meaningful reductions in ischemic occasions. The APPRAISE-2 Trial , among nine clinical trials analyzing apixaban in individuals vulnerable to ischemic events, was made to include approximately 10,800 sufferers with a recently available Acute Coronary Syndrome.